L-arginine improves uterine spiral arterial wall thickness in mouse models of preeclampsia

Main Article Content

Soetrisno Soetrisno
Sri Sulistyowati
Anwar Sandi Wibowo

Abstract

Background
Preeclampsia is a major cause of maternal and fetal morbidity and mortality. The imbalance of anti-angiogenic and angiogenic factors plays a role in endothelial dysfunction in preeclampsia. L-arginine is expected to improve the process of spiral artery remodeling. This study aims to examine the use of L-arginine to repair endothelial damage by measuring the thickness of uterine spiral arteries in mouse (Mus musculus) models of preeclampsia.

Methods
The researchers carried out an experimental study using 30 sixteen-day old pregnant Swiss mice (in good health, weighing 20-25 grams), which were randomly divided into 3 groups (each consisting of 10 mice). The groups were as follows: 1) normal pregnancy K(-); 2) preeclampsia model K(+); and 3) preeclampsia model receiving L-arginine (P). The authors performed histopathological examination of the mouse placenta, which had been dissected, embedded in paraffin wax and subsequently stained with hematoxylin and eosin (HE). The results were analyzed in SPSS v. 21 for Windows using Anova with Tukey.

Results
The mean thickness of spiral arteries in group K(-) was 53.95 + 26.96 mm, in K(+) 96.50 + 16.66 mm, and in P 62.79 + 8.04 mm. Statistically, there were significant differences between groups K(-) and K(+) (p=0.001) and between K(+) and P (p=0.000), but non-significant differences between K(-) and P (p=1.000).

Conclusions
The treatment with L-arginine proved to be effective in repairing endothelial damage by reducing intimal hyperplasia and atherosis and, in turn, the thickness of uterine spiral arteries in mouse models of preeclampsia.

Article Details

How to Cite
Soetrisno, S., Sulistyowati, S., & Wibowo, A. S. (2017). L-arginine improves uterine spiral arterial wall thickness in mouse models of preeclampsia. Universa Medicina, 36(2), 131–137. https://doi.org/10.18051/UnivMed.2017.v36.131-137
Section
Original Articles

References

World Health Organization. WHO recommendations for prevention and treatment of pre-eclampsia and eclampsia. Geneva: World Health Organisation;2011.

Burke SD, Karumanchi SA. Spiral artery remodelling in preeclampsia revisited. Hypertension 2013;62:1013–4.

Camacho E, Silva JA, Matos MG, et al. Actividad de las enzimas anti oxidantes en el rinon de la rata con preeclampsia experimental. ArchivosVen Farmacol Ter 2011;30:44–50.

Creasy RK, Resnik R, Iams JD, et al. Editors. Maternal-fetal medicine: principles and practice. 7th ed. Philadelphia, PA: Saunders;2014.

Cunningham FG, Leveno KJ, Bloom SL, et al. Editors. William obstetrics. 24th ed. New York: McGraw Hill Education;2014.

Al-Bayati MA, Ahmad MA, Khamas W. The potential effect of L-arginine on mice placenta. Adv Pharmacoepidemiol Drug Saf 2014;3:150. Doi: 10.4172/2167-1052.1000150.

Dorniak-Wall T, Grivell RM, Dekker GA, et al. The role of L-arginine in the prevention and treatment of pre-eclampsia: a systematic review of randomized trials. J Hum Hypertens 2014;28:230-5. Doi: 10.1038/jhh.2013.100.

Ekambaram P. HSP70 expression and its role in preeclamptic stress. Indian J Biochem Biophys 2011;48:243–55.

Stuehr DJ. Enzymes of the L-arginine to nitric oxide pathway. J Nutr 2004;134:2748S–51S.

George EM, Granger JP. Recent insights into the pathophysiology of preeclampsia. Expert Rev Obstet Gynecol 2010;5:557–66. Doi: 10.1586/eog.10.45.

Ghulmiyyah L, Sibai B. Maternal mortality from preeclampsia/eclampsia. Semin Perinatol 2012;36:56–9. Doi: 10.1053/j.semperi.2011. 09.011.

Alexander BT, Llinas MT, Kruckeberg WC, et al. L-arginine attenuates hypertension in pregnant rats with reduced uterine perfusion pressure. Hypertension 2004;43:832–6. Doi: 10.1161/01.HYP.0000119192.32360.a9.

Neri I, Jasonni VM, Gori GF, et al. Effect of L-arginine on blood pressure in pregnancy-induced hypertension: a randomized placebo-controlled trial. J Matern Fetal Neonatal Med 2006;19:277–81. Doi: 10.1080/14767050600587983.

Staff AC, Berge L, Haugen G, et al. Dietary supplementation with L-arginine or placebo in women with preeclampsia. Acta Obstet Gynecol Scand 2004;83:103–7.

Rytlewski K, Olszanecki R, Lauterbach R, et al. Effects of oral L-arginine on the foetal condition and neonatal outcome in preeclampsia: a preliminary report. Basic Clin Pharmacol Toxicol 2006;99:146–52. Doi: 10.1111/j.1742-7843.2006.pto_468.x.

Sulistyowati S, Bachnas MA, Anggraini ND, et al. Recombinant vascular endothelial growth factor 121 injection for the prevention of fetal growth restriction in a preeclampsia mouse model. J Perinat Med 2017;45:245–51. Doi: 10.1515/jpm-2016-0149.

Simbolon SE, Durry M, Lintong P. Gambaran histopatologi plasenta pada kehamilan dengan preeklampsia. Ebiomedik 2013;1:1069–74.

Gilbert JS, Babcock SA, Granger JP. Hypertension produced by reduced uterine perfusion in pregnant rats is associated with increased soluble fms-like tyrosine kinase-1 expression. Hypertension 2007;50:1142–7. Doi: 10.1161/HYPERTENSIONAHA.107.096594.

Hagmann H, Thadhani R, Benzing T, et al. The promise of angiogenic markers for the early diagnosis and prediction of preeclampsia. Clin Chem 2012;58:837–45. Doi: 10.1373/clinchem. 2011.169094.

Masuyama H, Nobumoto E, Segawa T, et al. Severe superimposed preeclampsia with obesity, diabetes, and mild imbalance of angiogenic factors. Acta Med Okayama 2012;66:171–5.

Kim JY, Kim YM. Acute atherosis of the uterine spiral arteries: clinicopathologic implications. J Pathol Transl Med 2015;49:462–71. Doi: 10.4132/jptm.2015.10.23.

Han L, Yang Z, Li K, at al. Antepartum or immediate postpartum renal biopsies in preeclampsia/eclampsia of pregnancy: new morphologic and clinical findings. Int J Clin Exp Pathol 2014;7:5129–43.

Li Z, Zhang Y, Ying MJ, et al. Recombinant vascular endothelial growth factor 121 attenuates hypertension and improves kidney damage in a rat model of preeclampsia. Hypertension 2017;50:686–92. Doi: 10.1161/HYPERTEN SIONAHA.107.092098.

Lukito JS, Dewi P. Gambaran histopatologi arteria spiralis alas plasenta pada preeklampsia / klampsia dan kehamilan normotensif. Majalah Kedokteran Nusantara 2007;40:173–9.

Playfair JH, Chain BM. Immunology at a glance. 9th ed. New Jersey: Wiley-Blackwell;2009.

Powe CE, Levine RJ, Karumachi SA. Preeclampsia, a disease of the maternal endothelium: the role of antiangiogenic factors and implications for later cardiovascular disease. Circulation 2011;123:2856–69. Doi: 10.1161/CIRCULATIONAHA.109.853127.

Pribadi A, Mose JC, Anwar AD. Patogenesis preeklampsia & manifestasi gejala klinis dalam kehamilan risiko tinggi perkembangan, implikasi & kontroversi. Mataram: Sagung Seto; 2015.

Roberts JM, Hubel CA. The two stage model of preeclampsia: variation on the theme. Placenta 2009;30 Suppl A:S32–S7. Doi: 10.1016/j. placenta.2008.11.009.